NeoPredics Preeclampsia Project: Empowering Better Outcomes for Mothers and Babies
Predicting Preeclampsia
Predicting Preeclampsia: A Lifesaving Initiative
Preeclampsia is one of the most urgent and dangerous challenges in maternal health today, contributing to approximately 500,000 infant deaths and 70,000 maternal deaths globally every year. Characterized by the sudden onset of high blood pressure during pregnancy, preeclampsia can lead to life-threatening complications such as preterm birth, organ failure, and, in severe cases, death.
At NeoPredics, we are committed to changing these alarming statistics. Our mission is to leverage advanced predictive analytics to revolutionize the detection and management of preeclampsia. Our innovative Preeclampsia Prediction Tool is built to deliver early, accurate insights, enabling clinicians to take preventive action when it matters most.
ADVANTAGES
A Three-Component Approach to
Preeclampsia Prevention and Care
Our unique approach combines AI-driven insights with continuous monitoring and predictive capabilities, transforming care for high-risk pregnancies from the 12th week onward.
- AI-Based Risk Assessment
Beginning at 12 weeks of pregnancy, our algorithm categorizes expectant mothers based on their risk of developing preeclampsia. Using data from electronic health records, this early identification allows healthcare providers to intervene before symptoms appear, setting the stage for proactive and individualized care. - Continuous Telemedical Monitoring
For high-risk pregnancies, our HIPAA-compliant telemedicine application regularly monitors vital signs. Healthcare providers receive early alerts if critical changes occur, enabling real-time interventions that can prevent escalation and reduce the need for emergency visits. - Predictive AI Prognosis of Adverse Events
In the third trimester, our system forecasts potential complications, including preterm delivery risks, empowering clinicians to anticipate and manage adverse events effectively. This predictive insight offers a window of opportunity to prepare for and address emerging risks before they impact the mother or child.
Preeclampsia by the Numbers
700.000
pregnancies affected
annually in
the U.S.
70.000
maternal deaths globally per year due to preeclampsia
500.000
infant deaths annually worldwide linked to preeclampsia complications
1 IN 12
pregnant women in the U.S. develop preeclampsia
2-3
times higher mortality rates among Black women due to preeclampsia complications
Impacting Maternal Health at Scale
In the U.S., maternal mortality is rising, especially among communities facing racial and socioeconomic disparities. With preeclampsia rates increasing, innovative tools like our Preeclampsia Prediction Tool offer a vital step forward in tackling these inequities. By focusing on early detection and prevention, we aim to lower preeclampsia complications and improve the quality of life for mothers and babies alike, ultimately contributing to healthier pregnancies on a global scale.
CONTACT US
Join Our Preeclampsia Journey:
Ready to Make a Difference?
Are you an obstetrician, midwife, nurse, or healthcare leader passionate about advancing maternal care? Join us in our mission to combat preeclampsia and protect mothers and their babies. Together, we can ensure that no woman becomes another statistic.
For more information or to become part of this initiative, contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. . Let’s work together to reshape maternal health and create safer, healthier futures for women and children everywhere.
NeoPredics AG (Switzerland)
Aeschengraben 20, 4051 Basel, Switzerland
Executive Team: Jörg Schmidt, Prof. Dr. Marc Pfister , Prof. Dr. Sven Wellmann
Registered office: Basel
Commercial register number CH-270.3.016.001-3
Chairman of the board: Dr. Gerhard Ries
NeoPredics USA, Inc. (US)
110 E Broward Blvd #1700
Fort Lauderdale, FL 33301, United States
Phone: +1 (954)-315-3884
NeoPredics AG (Germany)
Franz-Mayer-Straße 1, 93053 Regensburg
Excecutive Board: Thorsten Waloschek (chairman), Jörg Schmidt
Registered Office: Regensburg
Commercial register number: HRB 18679
Supervisory Board: Dr. Volker Pfahlert (chairman), Arne Kirchner, Prof. Dr. Marc Pfister, Dr. Gerhard Ries, Prof. Dr. Sven Wellmann
